Articles tagged with Alzheimer Disease
Researchers have identified a new mechanism of toxicity in Alzheimer's disease, where Aβ protein assemblies disrupt the neuronal membrane, leading to cell death. The study provides insight into the atomic structure of these assemblies and proposes targeting membrane pores to prevent neurotoxicity.
A new study from Massachusetts General Hospital reveals that different forms of phosphorylated tau can explain variable effects in Alzheimer's disease. The research found specific molecular characteristics associated with greater tau spread and worse disease progression.
A study found that middle-aged women are more likely to have changes in the brain related to Alzheimer's disease, even when controlling for age and other factors. The researchers suggest that hormonal changes during menopause may play a role in this increased risk.
A newly discovered gene RBFOX1 may drive the first appearance of amyloid plaques in the brain, contributing to Alzheimer's disease. The study found that variants of RBFOX1 increase protein fragments making up amyloid plaques and disrupt critical connections between neurons.
Researchers from Florida State University have uncovered new information about how Alzheimer's disease affects the brain during sleep. The study found that the interaction between two brain regions may contribute to symptoms experienced by patients, such as impaired memory and cognition. This discovery could lead to a better understand...
A combination of physical activity, not smoking, light-to-moderate alcohol consumption, high-quality diet, and cognitive activities reduced the risk of Alzheimer's disease by 60% among those with four or five healthy behaviors. The study included data from nearly 3,000 participants from two NIH-funded longitudinal study populations.
Researchers found amyloid β protein fibrillation slowed down in microgravity, resulting in distinct morphologies. The study provides fundamental insights into pathological amyloid formation, highlighting the ISS as an ideal experimental environment.
Scientists have developed a high-resolution model of protein strings typical for diabetes, revealing a strong similarity to those found in Alzheimer's disease. The findings suggest an increased risk of contracting diabetes in Alzheimer's patients and vice versa.
The Vietnam Era Twin Study of Aging will continue to follow and document risk factors for cognitive and brain aging in 1,600 male twins. The study aims to identify early signs of Alzheimer's disease and mild cognitive impairment.
A $3.3 million NIH grant will fund research into the structure and mechanisms of TDP-43, a protein linked to neurodegenerative conditions like ALS and Alzheimer's disease. The study aims to better understand how post-translational modifications affect TDP-43 assembly and interactions with therapeutic targets.
Researchers from DZNE and experts from US institutions study how noise in movement speed perception affects spatial navigation. They found that internal noise, accumulating with age, is the main cause of errors in determining position, leading to age-related orientation problems.
Scientists have found that baboons exhibit a steep age-related cognitive decline, similar to humans, making them a potentially useful model for testing early therapeutic interventions. The findings provide insight into the breakdown of brain systems and may lead to better treatments for Alzheimer's disease.
Research at DZNE reveals that experience encoding neurons interfere with memory containing neurons, disturbing recall of memories. Healthy mice and those with Alzheimer-like pathology were used to explore novel environments, showing a difference in brain activity.
Researchers develop lab-engineered model of human blood-brain barrier, discovering how APOE4 variant causes amyloid protein plaques to disrupt brain's vasculature. They identify specific vascular cell type and molecular pathway that promotes cerebral amyloid angiopathy pathology.
A new UCL-led study found that repetitive negative thinking is linked to cognitive decline and increased risk of Alzheimer's disease. The research, published in Alzheimer's & Dementia, suggests that psychological tools like mindfulness or meditation may help reduce dementia risk.
A new study shows that intranasal delivery of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) reduces inflammation in the brain, a prime factor in Alzheimer's disease. The treatment also triggers actions to guard against further degenerative effects.
A new study from the University of Eastern Finland found that antiepileptic drug use is associated with a significantly higher risk of death among people with Alzheimer's disease. The increased mortality risk was observed even after controlling for comorbidities and other factors.
Researchers found nilotinib reduced amyloid burden and tau tangles in neurons, suggesting it may aid in Alzheimer's treatment. The study also showed improved hippocampal volume loss and reduced phospho-tau-181 levels, hinting at a potential disease-modifying effect.
Researchers at Lund University and McGill University found that toxic tau protein spreads in the human brain via connected neurons, facilitated by beta-amyloid. The spread of toxic tau leads to widespread neuronal death and eventual dementia.
A $2.6M NIH award will examine how sex differences impact cognitive impairment and dementia, with a focus on the brain vascular system. The project aims to uncover personalized molecular targets for therapy and improve treatment of dementia.
Researchers at the University of Barcelona discovered two marine molecules, meridianine and lignarenone B, that can alter GSK3B activity without causing neurotoxic effects. These compounds promote neuronal plasticity and may offer a promising starting point for developing new drugs against Alzheimer's disease.
A new study has found that neurofilament light chain (NfL) levels in the blood can distinguish individuals at high risk of Alzheimer's disease at age 22, on average 22 years before their estimated age of cognitive impairment.
A new biomarker for Alzheimer's disease has been identified in the blood of patients, according to a recent study published in IJMS. The Ube2h gene was found to have increased specific expression in the blood of AD patients and AD model mice.
Researchers at the University of Missouri have found that menopause can reduce cognitive function and potentially play a role in Alzheimer's development in women. Animal studies using surgically induced menopause in rats showed poor memory and learning, indicating a decline in cognitive function.
Researchers discovered that aging neurons accumulate DNA damage, particularly oxidative 8-oxo-guanine lesions. Reactivating the enzyme HDAC1 can help repair this damage and improve cognitive function in mice.
Researchers at Duke University have developed a new imaging device that can measure the thickness and texture of the retina, potentially providing an early warning system for Alzheimer's disease. The device combines two technologies to spot structural changes in the retina, which could be indicative of the disease.
A new study developed a non-invasive molecular imaging approach using dynamic MRI to measure glucose level changes in the brain lymphatic system. This method helps identify Alzheimer's disease at early stages, allowing treatments to start promptly. The technique uses glucose as a 'tracer' and is compatible with existing MRI machines, m...
Researchers have developed a new imaging tool that detects widespread synaptic loss throughout the brain in early stages of Alzheimer's disease. This breakthrough enables scientists to identify areas of specific damage and monitor disease progression.
A study using mouse models of Alzheimer's disease found that high calcium levels in mitochondria are associated with plaque deposition and neuronal death. Researchers propose targeting calcium entry to the mitochondria as a promising new therapeutic approach.
A research team at the University of California, Irvine has been awarded $3.8 million to investigate epigenomic changes in the brain caused by Alzheimer's disease. The team aims to identify new therapeutic targets and biomarkers for early detection and treatment.
Researchers developed simple molecular reagents that can simultaneously target and modulate various pathogenic factors in Alzheimer's disease. The reagents displayed redox-dependent reactivities against free radicals, metal-free and metal-bound amyloid-beta, and led to chemical modifications that altered its aggregation.
Researchers developed an innovative approach to detect multiple proteins simultaneously using secondary-ion mass spectrometry. This technique surpasses existing fluorescence-based approaches, enabling the analysis of tens of proteins at once.
Researchers developed a compound that significantly reduced amyloid plaques, lessened brain inflammation, and diminished molecular markers of Alzheimer's disease. The findings suggest that drugs targeting different regions of amyloid-beta protein fragments and metal ions could improve outcomes for people with Alzheimer's.
A study of 161 Japanese adults with Alzheimer's disease found that day service users experienced significant improvements in cognitive function over six months. The Mini-Mental State Examination scores showed notable enhancements in orientation, attention, memory, language, and visual-spatial skills.
A 3D brain-like tissue model has demonstrated a possible causal relationship between sporadic Alzheimer's disease and herpes simplex virus I infection. The model allowed researchers to observe the formation of amyloid plaques, neuronal loss, and neuroinflammation in response to HSV-1 infection.
A study of 2,800 people aged 50 and older found that low intake of flavonoid-rich foods was linked to a higher risk of developing Alzheimer's disease. Consuming more berries, apples, and tea may help prevent the condition, with even small amounts providing benefits.
A new AI algorithm can predict Alzheimer's disease risk with high accuracy using a combination of brain MRI scans, cognitive impairment tests, and demographic data. The algorithm also provides interpretable visualizations of individual disease risk, leading to more accurate diagnoses.
Researchers have developed a method of lymphocytic vaccination to counter autoimmune diseases, proving clinically effective in treating multiple sclerosis and rheumatoid arthritis. The technology involves creating an immunology cell bank to enhance immunological protection against infection.
Matthew Disney's work has led to a new understanding of druggable targets and reinvigorated research on incurable diseases like Alzheimer's, Parkinson's, and ALS. His RNA-modifying tools show great applicability to cancers and rare genetic disorders.
The Ccr4-Not complex plays a crucial role in controlling protein production by degrading faulty mRNA. Defects in this complex may lead to incorrect protein concentrations, locations, or shapes, associated with various diseases including Alzheimer's.
Scientists have developed nanodevices that capture and trap beta-amyloid peptides, a key component of Alzheimer's plaques. The devices show promise in preventing plaque formation and reducing cell death, with over 90% efficiency compared to control particles.
A new study reveals how APOE4 triggers leaks in the brain's plumbing system, allowing toxic substances to seep into areas responsible for memory encoding and cognitive functions. The damage is linked to future problems in learning and memory, even when Alzheimer's signature sticky plaques have not appeared.
Systematic reviews evaluate cognitive tests for Alzheimer's disease, biomarkers for neuropathologic Alzheimer disease, and prescription drugs for cognitive dysfunction. The findings suggest that certain brief cognitive tests are highly sensitive for distinguishing clinical Alzheimer-type dementia from normal cognition.
Researchers found that decreasing neuroinflammation in the brain before memory problems and cognitive impairment were apparent may be beneficial. The new findings point to the importance of developing therapies that target very early stages of Alzheimer's disease.
A new review study found that three tests - amyloid PET, FDG-PET, and MRI - are highly accurate in distinguishing between Alzheimer's disease and other causes of dementia. These tests show promise in improving diagnosis, but more study is needed for standardization.
Ann McKee will lead a collaboration to characterize brain donors with and without a history of RHI and/or TBI, determining their neuropathological and clinical phenotypes. The goal is to identify the neuropathological features of TBI-related neurodegeneration and its association with dementia and parkinsonism.
A new blood test has been developed to detect Alzheimer's disease, which measures a specific variant of tau protein in ordinary blood samples. The test shows great promise for diagnosing and monitoring the condition early on, particularly in primary care settings.
Researchers used CRISPR/Cas9 to search for genes related to Alzheimer's disease and found that low levels of CIB1 lead to high amyloid beta production. The study suggests that regulating CIB1 and gamma secretase could be a new target for Alzhemier's disease therapy.
Researchers found that Alzheimer's disease can disrupt the absorption of oral medications through the digestive tract, leading to lower plasma concentrations. The study recommends revisiting dosing regimens for certain drugs in AD patients to ensure appropriate plasma ranges.
Researchers have identified genes implicated in neurodegeneration throughout the stages of Alzheimer's disease using gene-network analysis. The study found that protein domain networks collapse during the progression of AD, leading to neuronal dysfunction and neurodegeneration.
Researchers found that a specific gene variant, klotho, can protect against Alzheimer's disease in people with the ApoE4 high-risk gene variant. This finding could help identify individuals at lower risk and inform clinical trial participants and treatments.
A large-scale study has identified protein network changes that could be developed into treatment targets and fluid biomarkers for Alzheimer's disease. The research found that sets of proteins regulating glucose metabolism are strongly associated with Alzheimer's pathology and cognitive impairment.
A recent study published in Alzheimer's & Dementia found a strong association between mild behavioral impairment (MBI) and amyloid plaque deposits in the brains of elderly individuals. MBI may potentially serve as an early indicator of Alzheimer's disease, allowing for earlier diagnosis and intervention.
A new UCI-led study suggests that metabolic alterations, rather than just amyloid accumulation, contribute to the development of Alzheimer's disease in people with Down Syndrome. The study found similar energy metabolism deficits in adults with Down Syndrome and Alzheimer's disease, opening up new avenues for prevention.
Researchers developed a new technique to detect the aggregation state of amyloid beta proteins in solution, which could aid early diagnosis of Alzheimer's disease. The technique uses terahertz waves and provides a dementia quotient index to distinguish between protein states.
The A4 study found that higher levels of the amyloid protein in the brain are associated with an early stage of Alzheimer's disease. The study analyzed data from 4,486 participants and showed that amyloid burden is linked to a family history of disease, lower cognitive test scores, and reports of daily cognitive decline.
Researchers discovered a biomarker for early detection of Alzheimer's disease in the form of high levels of RNA produced by the PHGDH gene. The study, published in Current Biology, suggests that overproduction of extracellular RNA by the PHGDH gene in elderly individuals may serve as an early warning sign of Alzheimer's disease.
A study published in eLife found that amyloid plaque formation directly causes brain tissue loss in animals, leading to progressive memory loss and loss of brain matter. However, lithium has been shown to reduce the life-shortening effects of this loss, suggesting a potential strategy to slow Alzheimer's disease progression.
Researchers have identified a gene, endothelin-converting enzyme 2 (ECE2), that significantly increases the risk of Alzheimer's disease. The study found two mutations in ECE2 impairing its ability to break down amyloid beta protein, leading to increased levels and plaque formation.
Researchers at Lund University developed a new imaging method to study protein structures within nerve cells, providing insight into the first molecular changes in neurons affected by Alzheimer's disease. This breakthrough may help explain the mechanisms behind the disease and potentially lead to effective treatments.